Mitsubishi Tanabe Pharma

NCT00129805

Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)

NCT00059644

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059657

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00147316

Japan Alteplase Clinical Trial (J-ACT): Efficacy and Safety Study of Tissue Plasminogen Activator (Alteplase) for Ischemic Stroke

NCT00200343

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

NCT00259077

Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

NCT00259051

A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

NCT00147303

Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology Study

NCT00246922

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)

NCT00246935

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)

NCT00198588

Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia

NCT00691028

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

NCT00330681

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

NCT00415519

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

NCT00424463

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00451295

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

NCT00416520

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

NCT00500682

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)

NCT00501046

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

NCT00506441

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

NCT00542815

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00542386

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

NCT00727987

A Safety and Efficacy Study of Golimumab (CNTO 148) in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00771251

A Safety and Efficacy Study of Golimumab (CNTO148) in Patients With Active Rheumatoid Arthritis (RA)

NCT00780416

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

NCT00780910

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

NCT00772382

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00781274

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy

NCT00805766

Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)

NCT00858637

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

NCT02314637

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

NCT00974090

Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes

NCT00998881

Monotherapy Study of MP-513 in Patients With Type 2 Diabetes

NCT01026194

Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

NCT01072331

Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus

NCT01301833

Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes

NCT01387737

Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

NCT01413204

Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes

NCT01425632

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01468584

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

NCT01492686

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

NCT01532570

Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions

NCT01585155

Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis

NCT01580670

Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease

NCT01466192

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients

NCT01596335

Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

NCT01680159

A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis

NCT01625182

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

NCT01753557

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

NCT01753570

Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

NCT01840605

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

NCT01861522

The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01900054

A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

NCT01814917

Long-term Extension Study of MCI-196

NCT01818687

Safety and Tolerability Study of MCI-196

NCT01814904

Dose-finding Study of MCI-196

NCT02118961

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

NCT02220907

Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

NCT02327182

Safety Study of MT-4666 in Subjects With Alzheimer's Disease

NCT02354222

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

NCT02354235

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)

NCT02916706

Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus

NCT02924064

Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus

NCT02992925

Phase 3 Study of BK1310 in Healthy Infants

NCT03188692

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

NCT03329196

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

NCT03402386

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

NCT03439137

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

NCT03436693

Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

NCT03461146

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

NCT03645863

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

NCT03891758

Confirmatory Study of BK1310 in Healthy Infants

NCT04165824

Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04402489

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

NCT04577404

Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04569084

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05151471

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

NCT05198557

A Study of MT-0551 in Patients With Systemic Sclerosis

NCT05568615

Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS

NCT06144840

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP